| 4578 |
Otsuka Holdings Co., Ltd.
|
Strategy |
|
Completion of Rolling Submission of sBLA for IgA Nephropathy Treatment VOYXACT® (Cibeplernimab) in the United States
|
Oct 7, 2026
NEW
|
| 4410 |
Harima Chemicals Group, Inc.
|
Strategy |
|
Notice of Withdrawal from LAWTER (N.Z.) Business
|
Oct 7, 2026
NEW
|
| 6255 |
NPC Incorporated
|
Strategy |
|
Medium-Term Management Plan
|
Oct 7, 2026
NEW
|
| 4599 |
StemRIM
|
Strategy |
|
Notice of US Patent Registration for Stem Cell Gene Therapy Technology for Recessive Dystrophic Epidermolysis Bullosa (Development Code: SR-GT1)
|
Oct 7, 2026
NEW
|
| 4416 |
True Data Inc.
|
Strategy |
|
Supplementary Information on True Data Inc.’s Acquisition of Cosmonet as a Wholly Owned Subsidiary
|
Oct 7, 2026
NEW
|
| 4176 |
coconala Inc.
|
Strategy |
|
Notice of Acquisition of Shares of Acrosstudio Inc. (Subsidiarization)
|
Oct 7, 2026
NEW
|
| 2998 |
CREAL Inc.
|
Strategy |
|
CREAL: Formation of Funds in September 2026
|
Oct 7, 2026
NEW
|
| 6573 |
CRAVIA Inc.
|
M&A |
|
Notice Regarding Capital and Business Alliance through Share Transfer and Working Capital Loan
|
Oct 6, 2026
NEW
|
| 4212 |
Sekisui Jushi Corporation
|
M&A |
|
Acquisition of Management Rights of Traffic Safety Business Companies in South Korea and Vietnam
|
Oct 6, 2026
NEW
|
| 4591 |
Ribomic Inc.
|
Strategy |
|
Announcement on Progress of Phase II Long-Term Dosing Trial of Umedaptanib Pegol for Achondroplasia and Continued Efficacy in Responding Patients
|
Oct 6, 2026
|
| 7012 |
Kawasaki Heavy Industries, Ltd.
|
Strategy |
|
Group Vision 2030 Progress Briefing
|
Oct 6, 2026
|
| 4582 |
SymBio Pharmaceuticals Limited
|
Strategy |
|
Initiation of Consultations for Conditional Marketing Authorization (CMA) in the UK for Brincidofovir (BCV)
|
Oct 6, 2026
|
| 9503 |
The Kansai Electric Power Company, Incorporated
|
Strategy |
|
Overview of Revisions to Low-Voltage Electricity Rate Plans in the Tokyo Metropolitan Area
|
Oct 5, 2026
|
| 2531 |
Takara Holdings Inc.
|
M&A |
|
Notice Regarding Transfer of Shares Involving a Consolidated Subsidiary and Recognition of Extraordinary Income
|
Oct 5, 2026
|
| 4889 |
Renascience Inc.
|
M&A |
|
Notice of Completion of Patient Enrollment in Phase III Trial of Nivolumab Combined with RS5614 for Unresectable Malignant Melanoma
|
Oct 5, 2026
|
| 3612 |
World Co., Ltd.
|
M&A |
|
Notice of Establishment of a New Company and Its Subsidiarization for the Business Succession of Uchino Co., Ltd. by W&D Investment Design, Inc.
|
Oct 5, 2026
|
| 4507 |
Shionogi & Co., Ltd.
|
M&A |
|
Notice Regarding the Acquisition of IntraBio, Inc. as a Wholly Owned Subsidiary in the United States
|
Oct 5, 2026
|
| 4527 |
Rohto Pharmaceutical Co.,Ltd.
|
Strategy |
|
“Medium- to Long-Term Growth Strategy 2026” – Rolling Update of “Rohto Group Medium- to Long-Term Growth Strategy 2025–2035” and Notice Regarding the 2031 Financial Forecast
|
Oct 5, 2026
|
| 9236 |
Japan M&A Solution Incorporated
|
M&A |
|
Notice of Conclusion of Share Exchange Agreement to Make SBI Tsuji-Hongo M&A Co., Ltd. a Wholly Owned Subsidiary and Planned Changes in Major Shareholders, Other Related Companies and Specific Subsidiaries
|
Oct 5, 2026
|
| 4578 |
Otsuka Holdings Co., Ltd.
|
Strategy |
|
Commencement of NDA Submission under FDA RTOR Program for Zipareltinib Combined with Chemotherapy as First-line Treatment for NSCLC with EGFR Exon 20 Insertions
|
Oct 2, 2026
|
